Asthma Diagnosis and Management
Introduction to FeNO Measurement
- The American Thoracic Society recommends exhaled nitric oxide (FeNO) measurement as a valuable non-invasive biomarker for diagnosing eosinophilic airway inflammation and predicting steroid responsiveness in patients with respiratory symptoms 1
Diagnosis of Eosinophilic Airway Inflammation
- FeNO serves as an indirect marker for up-regulation of airway inflammation, providing objective evidence of inflammation when clinical assessment is uncertain 1
- FeNO measurement is a non-invasive alternative to more invasive procedures like bronchoscopy, lavage, biopsy, or induced sputum, and is supported by the American Thoracic Society and American Academy of Pediatrics 1, 2
Prediction of Steroid Responsiveness
- High FeNO values strongly predict likelihood of response to corticosteroid therapy, helping avoid unnecessary "trial of steroids" or long-term corticosteroid treatment, as indicated by the American College of Chest Physicians and American Thoracic Society 1
- A high FeNO value predicts likely responsiveness to inhaled corticosteroid (ICS) therapy, with strong predictive value, and elevated FeNO is associated with increased risk of asthma exacerbations and loss of control when inhaled steroids are reduced or withdrawn 1, 3
Interpretation of FeNO Results
- The American Thoracic Society (ATS) guidelines recommend the following cut-off values for FeNO:
| Category | Adults (ppb) | Children (ppb) |
|---|---|---|
| Low | <25 | <20 |
| Intermediate | 25-50 | 20-35 |
| High | >50 | >35 |
- A FeNO value >50 ppb strongly indicates the presence of eosinophilic airway inflammation, while a value <25 ppb indicates that eosinophilic airway inflammation is unlikely, and alternative diagnoses should be considered, as stated by the American College of Chest Physicians and American Academy of Allergy, Asthma, and Immunology 1
- Intermediate FeNO values (25-50 ppb) should be interpreted with caution and in clinical context, as suggested by the National Asthma Education and Prevention Program and American Academy of Allergy, Asthma, and Immunology 1, 5
- A significant response to anti-inflammatory therapy is indicated by a reduction of at least 20% in FeNO for values over 50 ppb, or a reduction of more than 10 ppb for values lower than 50 ppb, according to the American Thoracic Society and American College of Chest Physicians 1, 3
Factors Affecting FeNO Levels
- Age, height, sex, and atopy status can affect FeNO levels, as noted by the American Academy of Pediatrics and American College of Chest Physicians 1
- Smoking reduces FeNO levels, potentially leading to false-negative results, as stated by the American College of Chest Physicians 1
- Other factors that can affect FeNO levels include recent respiratory infections and diet, as noted by the American Thoracic Society and American Academy of Allergy, Asthma, and Immunology 1, 5
Clinical Application of FeNO
- FeNO should be interpreted alongside clinical symptoms and lung function tests, not in isolation, as recommended by the National Asthma Education and Prevention Program and American Thoracic Society 1, 6
- Pulmonary function tests (PFTs), including spirometry, demonstrate airflow obstruction, show reversibility of obstruction, and provide objective measurement of lung function, with bronchodilator reversibility testing supporting asthma diagnosis when improvement in FEV1 ≥12% and ≥200mL after bronchodilator administration is observed 6
- FeNO should not be used in isolation for diagnosis or management decisions but integrated with clinical assessment and other tests, as recommended by the American Thoracic Society and American College of Allergy, Asthma, and Immunology 1, 5
- Not all asthma is associated with high FeNO, such as non-eosinophilic/neutrophilic asthma which may have normal FeNO, and overreliance on absolute FeNO values, ignoring confounding factors, and using FeNO in very young children should be avoided 5, 1
Monitoring and Management
- Serial FeNO measurements help determine trends and monitor treatment efficacy, and persistently high FeNO despite prescribed ICS therapy may indicate poor adherence or incorrect inhaler technique, as noted by the American Thoracic Society and American College of Chest Physicians 1, 3
- Regular spirometry and peak flow monitoring are essential for assessing lung function stability and detecting variability, with the ATS recommending FeNO for monitoring airway inflammation in asthma patients, though the quality of evidence is rated as low 6, 1, 7
- The ATS and the American College of Allergy, Asthma, and Immunology recommend against using FeNO as the sole diagnostic criterion due to its moderate specificity and variable sensitivity in different asthma phenotypes, and suggest FeNO-based care as a conditional recommendation, with the 2020 NAEPP guidelines noting that FeNO should not be the sole measure for asthma management 5, 1, 8